Mario Sznol

68.8k citations
270 papers · 19.8k indexed · 12 hit papers · h-index 67

Impact in

  • Oncology top 0.05%
    • Cancer Immunotherapy and Biomarkers
    • CAR-T cell therapy research
  • Immunology top 0.1%
    • Immunotherapy and Immune Responses
    • Immune Cell Function and Interaction

Papers in

    • Cancer Immunotherapy and Biomarkers 154
    • CAR-T cell therapy research 96
    • Colorectal Cancer Treatments and Studies 19
    • Immunotherapy and Immune Responses 70
    • Immune Cell Function and Interaction 20

Mario Sznol

266 papers receiving 19.4k citations

Hit Papers

T cell characteristics associated with toxicity to immune checkpoint blockade in patients with melanoma 2022 · 180 citations
180199520262005201550010001.5k

Peers

Mario Sznol
Comparison fields: 5 of 137
  • Oncology 13.8k
  • Immunology 7.8k
  • Biotechnology 1.3k
  • Pulmonary and Respiratory Medicine 4.3k
  • Genetics 1.1k
Replace Patrick Hwu with:
Patrick Hwu United States
Robert H. Vonderheide United States
Padmanee Sharma United States
Richard M. Sherry United States
David P. Carbone United States
Paolo A. Ascierto Italy
Omid Hamid United States
James L. Gulley United States
Michele Maio Italy
Christina B. Walter Germany
Mario Sznol relative to Patrick Hwu United States Patrick Hwu's profile →
Citations per field
00.5×1.5×2.3×
Patrick Hwu · 1×
Citations per year

Countries citing papers authored by Mario Sznol

Since Specialization
Citations

This map shows the geographic impact of Mario Sznol's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Mario Sznol with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Mario Sznol more than expected).

Fields of papers citing papers by Mario Sznol

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Mario Sznol. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Mario Sznol. The network helps show where Mario Sznol may publish in the future.

Co-authors

The 25 scholars most cited alongside Mario Sznol, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Mario Sznol Line = papers co-authored together Mario Sznol links everyone, so they are left out of the graph.

All Works

20 of 20 papers shown
#Work
1 20250
2 20231
3 20231
4 20227
5 202052
6 2020165
7 2019169
8 201823
9 2017183
10 201753
11 2017111
12
Results from an Integrated Safety Analysis of Urelumab, an Agonist Anti-CD137 Monoclonal Antibody
Hit paper breakdown →
2016281
13 2016111
14 2015163
15 201467
16
A Phase I study of IMCgp100: durable responses with a novel first-in-class immunotherapy for advanced melanoma
20141
17 201177
18 200934
19
Phase I Study of the Intravenous Administration of AttenuatedSalmonella typhimuriumto Patients With Metastatic Melanoma
Hit paper breakdown →
2002565
20
Phase i study of high dose continuous infusion interleukin 2 and autologous lymphokine activated killer cells in patients with metastatic or unresectable malignant melanoma and renal cell carcinoma
19891

About Mario Sznol

Mario Sznol is a scholar working on Oncology, Immunology, Biotechnology, Cancer Research and Pulmonary and Respiratory Medicine, having authored 270 papers that have together received 19.8k indexed citations. Recurring topics across this work include Cancer Immunotherapy and Biomarkers (154 papers), CAR-T cell therapy research (96 papers), Immunotherapy and Immune Responses (70 papers), Melanoma and MAPK Pathways (37 papers), Renal cell carcinoma treatment (23 papers), Immune Cell Function and Interaction (20 papers), Monoclonal and Polyclonal Antibodies Research (20 papers) and Colorectal Cancer Treatments and Studies (19 papers). The work is most often cited by research in Oncology (13.8k citations), Immunology (7.8k citations), Biotechnology (1.3k citations), Pulmonary and Respiratory Medicine (4.3k citations) and Genetics (1.1k citations). Mario Sznol has collaborated with scholars based in United States, France and United Kingdom. Frequent co-authors include Harriet M. Kluger, Richard I. Fisher, Michael B. Atkins, Lieping Chen, David Parkinson, Jedd D. Wolchok, Kim Margolin, Steven A. Rosenberg, F. Stephen Hodi and Lori Kunkel. Their work appears in journals such as Journal of Clinical Oncology, Clinical Cancer Research, Annals of Oncology, Journal for ImmunoTherapy of Cancer and Cancer Research.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Rankless by CCL
2026